BLAINJECTIONINJECTABLEPriority Review
Approved
Jun 2023
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
20
Mechanism of Action
CD20-directed Antibody Interactions
Pharmacologic Class:
Bispecific CD20-directed CD3 T Cell Engager
Clinical Trials (5)
An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
Started Sep 2025
300 enrolled
Diffuse Large B-Cell Lymphoma
A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma
Started Jun 2025
0B-cell Lymphoma
Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL
Started Jun 2025
38 enrolled
Diffuse Large B-Cell Lymphoma
Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial
Started May 2025
27 enrolled
Mantle Cell Lymphoma
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Started Apr 2025
50 enrolled
Lymphoma